US Patent

US11253472 — Oral cannabinoid formulations

Composition of Matter · Assigned to Benuvia Therapeutics Inc · Expires 2028-08-06 · 2y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects oral formulations of a cannabinoid, specifically dronabinol, that are stable at room or refrigerated temperatures.

USPTO Abstract

Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.

Drugs covered by this patent

Patent Metadata

Patent number
US11253472
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-08-06
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Benuvia Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.